6 hours ago
Novo Nordisk is approaching the expiration of patent rights for its blockbuster weight loss medication, Ozempic, in India, China, Canada, and several other nations. This development is expected to allow the introduction of lower-cost generic alternatives in these markets, increasing accessibility for patients seeking treatment.
